Press Release issued Jan 13, 2021: Frontida BioPharm, Inc. announced today the launch of its new Category 1 (CAT.ONETM) in vitro testing and evaluation services to support the development and regulatory approvals for abuse-deterrent formulations of pain management and Central Nervous System (CNS) targeted therapies.
Frontida BioPharm, Inc. has Been Recognized as a Minority Owned Contract Development and Manufacturing Organization
This recognition from the NMSDC & EMSDC represents Frontida’s work to create and maintain jobs, among other processes. The NMSDC helps certified businesses find new opportunities and avenues for growth, making the future of Frontida even more exciting.
Puneet Sapra joins Frontida with the goal of accelerating corporate growth in his position as CFO. His experience in the industry, gained at some of the most influential and well-known companies in the healthcare industry, will help Frontida optimize our growth strategies. The team is excited to begin working with Mr. Sapra and participate in the processes he will lead.
Praful Agrawala joins Frontida to bolster and lead our new technology and product development efforts. His know-how gained from leading product development and launch efforts at innovative pharmaceutical companies, coupled with wide-ranging pharmaceutics knowledge will help Frontida continue to innovate and implement new manufacturing technologies.
Steven Roese has an extensive background with important and relevant experience and will work to bolster Frontida’s operational workflow. With his impressive history in the industry, Frontida is excited for Mr. Roese to confidently step into his responsibilities and be a leader within the company.